Our Partner Sponsors

Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key therapeutic areas: medical aesthetics, eye care, central nervous system and gastroenterology.

As part of their approach to delivering innovation for better patient care, Allergan has built one of the broadest pharmaceutical and device research and development pipelines in the industry.

Being a truly global company, they work in over 70 countries and serve patients in more than 140 countries. Alcon has a long history of industry firsts, and each year they commit a substantial amount in Research and Development to meet customer needs.

In 2011, Santen purchased Santen S.A.S. (formally known as Novagali), a French ophthalmic pharmaceutical company that has excellent R&D capability and drug formulation technologies in the dry eye field.

This purchase has reinforced Santen's development pipelines, enhancing its international competitiveness in the ophthalmic field.

To speed up clinical development, Santen has relocated its hub to the United States (Santen Inc.), where clinical trials can be conducted in a relatively short time.

To improve the quality and efficiency of clinical development, they are building a system to conduct early-stage clinical development in the United States, while conducting the late-stage clinical development in Japan, the United States, Europe, China and other Asian countries, as well as in other emerging countries.

The company retains a lean, adaptable structure, working with service providers and consultants managed by a team of experienced business-founders.